{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:00:16Z","timestamp":1782136816409,"version":"3.54.5"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.steroids.2022.109036","type":"journal-article","created":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T10:46:16Z","timestamp":1649501176000},"page":"109036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Estrogen receptor expression is modulated in human and mouse prostate epithelial cells during cancer progression"],"prefix":"10.1016","volume":"184","author":[{"given":"Sushama","family":"Gadkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohini","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junita","family":"Desouza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Bhowmick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vainav","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uddhav","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kshitish K.","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetanjali","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.steroids.2022.109036_b0005","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030361","article-title":"The epidemiology of prostate cancer","volume":"8","author":"Pernar","year":"2018","journal-title":"Cold Spring Harbor Perspect. Med."},{"key":"10.1016\/j.steroids.2022.109036_b0010","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.695170","article-title":"Does exist a differential impact of degarelix versus LHRH agonists on cardiovascular safety? Evidences from randomized and real-world studies","volume":"12","author":"Sciarra","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.steroids.2022.109036_b0015","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13045-020-00978-z","article-title":"Novel therapies are changing treatment paradigms in metastatic prostate cancer","volume":"13","author":"Powers","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.steroids.2022.109036_b0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/pros.23446","article-title":"Estrogen receptor signaling in prostate cancer: implications for carcinogenesis and tumor progression","volume":"78","author":"Bonkhoff","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.steroids.2022.109036_b0025","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/sj.bjc.6690445","article-title":"Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies","volume":"80","author":"Eaton","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.steroids.2022.109036_b0030","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1158\/1055-9965.EPI-04-0371","article-title":"Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era","volume":"14","author":"Platz","year":"2005","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.steroids.2022.109036_b0035","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/pros.20588","article-title":"Androgens and prostate cancer risk: a prospective study","volume":"67","author":"Wiren","year":"2007","journal-title":"Prostate"},{"key":"10.1016\/j.steroids.2022.109036_b0040","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/bjc.1988.46","article-title":"The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring","volume":"57","author":"Henderson","year":"1988","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.steroids.2022.109036_b0045","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1210\/jc.2003-030933","article-title":"Local aromatase expression in human prostate is altered in malignancy","volume":"89","author":"Ellem","year":"2004","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"10.1016\/j.steroids.2022.109036_b0050","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1200\/JCO.2007.11.0908","article-title":"Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens","volume":"25","author":"Cussenot","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.steroids.2022.109036_b0055","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/pros.2990130406","article-title":"The periurethral zone of the prostate of the cynomolgus monkey is the most sensitive prostate part for an estrogenic stimulus","volume":"13","author":"Habenicht","year":"1988","journal-title":"Prostate"},{"key":"10.1016\/j.steroids.2022.109036_b0060","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/pros.2990160307","article-title":"Quantitation of cytosolic and nuclear estrogen and progesterone receptor in benign, untreated, and treated malignant human prostatic tissue by radioligand binding and enzyme-immunoassays","volume":"16","author":"Mobbs","year":"1990","journal-title":"Prostate"},{"key":"10.1016\/j.steroids.2022.109036_b0065","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1172\/JCI108353","article-title":"The induction of prostatic hypertrophy in the dog with androstanediol","volume":"57","author":"Walsh","year":"1976","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.steroids.2022.109036_b0070","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/carcin\/16.6.1311","article-title":"Induction at high incidence of ductal prostate adenocarcinomas in NBL\/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol","volume":"16","author":"Bosland","year":"1995","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.steroids.2022.109036_b0075","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/pros.2990230307","article-title":"Endocrine and antiprostatic effects of raloxifene (LY156758) in the male rat","volume":"23","author":"Neubauer","year":"1993","journal-title":"Prostate"},{"key":"10.1016\/j.steroids.2022.109036_b0080","first-page":"1370","article-title":"Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model","volume":"62","author":"Raghow","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2022.109036_b0085","doi-asserted-by":"crossref","unstructured":"D. Price, B. Stein, P. Sieber, R. Tutrone, J. Bailen, E. Goluboff, D. Burzon, D. Bostwick, M. Steiner, Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial, The Journal of urology. 176 (2006) 965-70; discussion 970-1. 10.1016\/j.juro.2006.04.011.","DOI":"10.1016\/j.juro.2006.04.011"},{"key":"10.1016\/j.steroids.2022.109036_b0090","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1186\/s12885-015-1871-z","article-title":"Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial","volume":"15","author":"Fujimura","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.steroids.2022.109036_b0095","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2174\/138920206779315737","article-title":"Estrogen signaling multiple pathways to impact gene transcription","volume":"7","author":"Marino","year":"2006","journal-title":"Curr. Genomics"},{"key":"10.1016\/j.steroids.2022.109036_b0100","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1210\/me.2004-0480","article-title":"A life-long search for the molecular pathways of steroid hormone action","volume":"19","author":"O'Malley","year":"2005","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.steroids.2022.109036_b0105","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.steroids.2007.10.013","article-title":"The role of estrogens and estrogen receptors in normal prostate growth and disease","volume":"73","author":"Prins","year":"2008","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2022.109036_b0110","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1093\/emboj\/19.17.4688","article-title":"Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1","volume":"19","author":"Flouriot","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.steroids.2022.109036_b0115","doi-asserted-by":"crossref","first-page":"13162","DOI":"10.1073\/pnas.0605676103","article-title":"Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling","volume":"103","author":"Leung","year":"2006","journal-title":"PNAS"},{"key":"10.1016\/j.steroids.2022.109036_b0120","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.bbrc.2005.08.226","article-title":"Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66","volume":"336","author":"Wang","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.steroids.2022.109036_b0125","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0002-9440(10)65160-7","article-title":"Estrogen receptor expression in prostate cancer and premalignant prostatic lesions","volume":"155","author":"Bonkhoff","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.steroids.2022.109036_b0130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jsbmb.2004.10.016","article-title":"Role of estrogens in development of prostate cancer","volume":"92","author":"Harkonen","year":"2004","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2022.109036_b0135","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0002-9440(10)61676-8","article-title":"Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma","volume":"159","author":"Leav","year":"2001","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.steroids.2022.109036_b0140","doi-asserted-by":"crossref","first-page":"604","DOI":"10.18632\/oncotarget.2820","article-title":"Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity","volume":"6","author":"Takizawa","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.steroids.2022.109036_b0145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/fonc.2018.00002","article-title":"Estrogens and Their Receptors in Prostate Cancer: Therapeutic Implications","volume":"8","author":"Di Zazzo","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.steroids.2022.109036_b0150","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1677\/ERC-09-0294","article-title":"Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion","volume":"17","author":"Leung","year":"2010","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.steroids.2022.109036_b0155","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/pros.22814","article-title":"Epithelial-to-mesenchymal transition and estrogen receptor alpha mediated epithelial dedifferentiation mark the development of benign prostatic hyperplasia","volume":"74","author":"Shao","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.steroids.2022.109036_b0160","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/pros.23404","article-title":"Estradiol promotes epithelial-to-mesenchymal transition in human benign prostatic epithelial cells","volume":"77","author":"Shi","year":"2017","journal-title":"Prostate"},{"issue":"42","key":"10.1016\/j.steroids.2022.109036_b0165","doi-asserted-by":"crossref","first-page":"44388","DOI":"10.18632\/oncotarget.6317","article-title":"Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer","volume":"6","author":"Mishra","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.steroids.2022.109036_b0170","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3389\/fendo.2020.00184","article-title":"Estrogen receptors promote migration, invasion and colony formation of the androgen-independent prostate cancer cells PC-3 through beta-catenin pathway","volume":"11","author":"Lombardi","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.steroids.2022.109036_b0175","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1038\/ncomms6383","article-title":"The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer","volume":"5","author":"Chakravarty","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.steroids.2022.109036_b0180","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12964-019-0367-x","article-title":"Estrogen receptor alpha-NOTCH1 axis enhances basal stem-like cells and epithelial-mesenchymal transition phenotypes in prostate cancer","volume":"17","author":"Shen","year":"2019","journal-title":"Cell Commun. Signaling: CCS"},{"key":"10.1016\/j.steroids.2022.109036_b0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226057","article-title":"Estrogen receptor beta exerts tumor suppressive effects in prostate cancer through repression of androgen receptor activity","volume":"15","author":"Chaurasiya","year":"2020","journal-title":"PLoS ONE"},{"key":"10.1016\/j.steroids.2022.109036_b0190","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1038\/onc.2013.384","article-title":"Estrogen receptor beta upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer","volume":"33","author":"Dey","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.steroids.2022.109036_b0195","doi-asserted-by":"crossref","first-page":"26347","DOI":"10.1073\/pnas.2007160117","article-title":"Estrogen receptor beta regulates AKT activity through up-regulation of INPP4B and inhibits migration of prostate cancer cell line PC-3","volume":"117","author":"Chaurasiya","year":"2020","journal-title":"PNAS"},{"key":"10.1016\/j.steroids.2022.109036_b0200","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1210\/me.2012.1227","article-title":"Estrogen receptors beta1 and beta2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3","volume":"26","author":"Dey","year":"2012","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.steroids.2022.109036_b0205","article-title":"Estrogen receptor beta2 induces hypoxia signature of gene expression by stabilizing HIF-1alpha in prostate cancer","volume":"10","author":"Dey","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.steroids.2022.109036_b0210","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/mc.23099","article-title":"Membrane-initiated estrogen signaling in prostate cancer: A route to epithelial-to-mesenchymal transition","volume":"58","author":"Gadkar","year":"2019","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.steroids.2022.109036_b0215","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22031153","article-title":"Estrogen Receptor Signaling Pathways Involved in Invasion and Colony Formation of Androgen-Independent Prostate Cancer Cells PC-3","volume":"22","author":"Lombardi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.steroids.2022.109036_b0220","first-page":"4096","article-title":"Metastatic prostate cancer in a transgenic mouse","volume":"56","author":"Gingrich","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2022.109036_b0225","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1073\/pnas.92.8.3439","article-title":"Prostate cancer in a transgenic mouse","volume":"92","author":"Greenberg","year":"1995","journal-title":"PNAS"},{"key":"10.1016\/j.steroids.2022.109036_b0230","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/carcin\/bgt156","article-title":"High circulating estrogens and selective expression of ERbeta in prostate tumors of Americans: implications for racial disparity of prostate cancer","volume":"34","author":"Abd Elmageed","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.steroids.2022.109036_b0235","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/pros.10215","article-title":"Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model","volume":"55","author":"Kaplan-Lefko","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.steroids.2022.109036_b0240","first-page":"59","article-title":"Prostate epithelial stem cell isolation and culture","volume":"81","author":"Hudson","year":"2003","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.steroids.2022.109036_b0245","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1158\/1541-7786.MCR-05-0098","article-title":"Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer","volume":"4","author":"Nanni","year":"2006","journal-title":"Mol. Cancer Res.: MCR"},{"key":"10.1016\/j.steroids.2022.109036_b0250","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1006\/bbrc.2001.6038","article-title":"Differential expression of estrogen receptor beta (ERbeta) and its C-terminal truncated splice variant ERbetacx as prognostic predictors in human prostatic cancer","volume":"289","author":"Fujimura","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.steroids.2022.109036_b0255","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.mce.2004.08.012","article-title":"Frequent loss of estrogen and progesterone receptors in human prostatic tumors determined by quantitative real-time PCR","volume":"229","author":"Ji","year":"2005","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.steroids.2022.109036_b0260","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1677\/joe.0.1680447","article-title":"Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate","volume":"168","author":"Royuela","year":"2001","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.steroids.2022.109036_b0265","first-page":"79","article-title":"Expression of estrogen alpha and beta receptors in prostate cancer and hyperplasia: Immunohistochemical analysis, African","volume":"16","author":"Al-Maghrabi","year":"2010","journal-title":"J. Urol."},{"key":"10.1016\/j.steroids.2022.109036_b0270","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/pros.20929","article-title":"Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue","volume":"69","author":"Walton","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.steroids.2022.109036_b0275","first-page":"11","article-title":"The ubiquitin-like molecule interferon-stimulated gene 15 is overexpressed in human prostate cancer","volume":"23","author":"Satake","year":"2010","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.steroids.2022.109036_b0280","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/hupa.2002.124033","article-title":"Prostate carcinoma expression of estrogen receptor-beta as detected by PPG5\/10 antibody has positive association with primary Gleason grade and Gleason score","volume":"33","author":"Torlakovic","year":"2002","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.steroids.2022.109036_b0285","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/pros.10171","article-title":"Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma","volume":"54","author":"Fixemer","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.steroids.2022.109036_b0290","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0303-7207(01)00418-X","article-title":"Estrogen receptor beta expression in human prostate tissue","volume":"178","author":"Pasquali","year":"2001","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.steroids.2022.109036_b0295","first-page":"239","article-title":"Expression of estrogen receptor-B (ER-B) in bengin and malignant prostatic epithelial cells and its correlation with the clinico-pathological features","volume":"19","author":"Gabal","year":"2007","journal-title":"J. Egyptian National Cancer Inst."},{"key":"10.1016\/j.steroids.2022.109036_b0300","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1530\/ERC-12-0402","article-title":"Estrogen receptor beta expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease","volume":"20","author":"Zellweger","year":"2013","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.steroids.2022.109036_b0305","first-page":"2051","article-title":"Loss of estrogen receptor \u03b2 expression in malignant human prostate cells in primary cultures and in prostate cancer tissues1","volume":"86","author":"Pasquali","year":"2001","journal-title":"J. Clin. Endocrinol. Metabolism."},{"key":"10.1016\/j.steroids.2022.109036_b0310","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4103\/IJPM.IJPM_467_18","article-title":"Immunoexpression of estrogen receptor-\u03b2 and progesterone receptor in prostate adenocarcinoma, does it inhibit neoplastic proliferation and invasion?","volume":"63","author":"Bera","year":"2020","journal-title":"Indian J. Pathol. Microbiol."},{"key":"10.1016\/j.steroids.2022.109036_b0315","first-page":"5331","article-title":"Frequent loss of estrogen receptor-beta expression in prostate cancer","volume":"61","author":"Horvath","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2022.109036_b0320","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s12253-014-9870-y","article-title":"Expression of estrogen receptor beta and Ki 67 in benign & malignant human prostate lesions by immunohistochemistry","volume":"21","author":"Grover","year":"2015","journal-title":"Pathol. Oncol. Res.: POR"},{"key":"10.1016\/j.steroids.2022.109036_b0325","first-page":"2051","article-title":"Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues","volume":"86","author":"Pasquali","year":"2001","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"10.1016\/j.steroids.2022.109036_b0330","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1210\/en.2010-1377","article-title":"Estrogen-initiated transformation of prostate epithelium derived from normal human prostate stem-progenitor cells","volume":"152","author":"Hu","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2022.109036_b0335","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12672-019-00360-7","article-title":"Role of Estrogen in Androgen-Induced Prostate Carcinogenesis in NBL Rats","volume":"10","author":"Ozten","year":"2019","journal-title":"Hormones & Cancer"},{"key":"10.1016\/j.steroids.2022.109036_b0340","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.trsl.2020.04.003","article-title":"Effects of estrogen receptor signaling on prostate cancer carcinogenesis","volume":"222","author":"Qu","year":"2020","journal-title":"Transl. Res."},{"key":"10.1016\/j.steroids.2022.109036_b0345","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1210\/en.2012-1030","article-title":"Aggressive prostate cancer is prevented in ERalphaKO mice and stimulated in ERbetaKO TRAMP mice","volume":"153","author":"Slusarz","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2022.109036_b0350","doi-asserted-by":"crossref","unstructured":"J.T. Lei, X. Gou, S. Seker, M.J. Ellis, ESR1 alterations and metastasis in estrogen receptor positive breast cancer, Journal of cancer metastasis and treatment. 5 (2019) 10.20517\/2394-4722.2019.12.","DOI":"10.20517\/2394-4722.2019.12"},{"key":"10.1016\/j.steroids.2022.109036_b0355","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.humpath.2019.04.009","article-title":"Tissue-specific quantification and localization of androgen and estrogen receptors in prostate cancer","volume":"89","author":"Sehgal","year":"2019","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.steroids.2022.109036_b0360","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3816\/CGC.2003.n.009","article-title":"Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia","volume":"2","author":"Steiner","year":"2003","journal-title":"Clinical prostate cancer."},{"key":"10.1016\/j.steroids.2022.109036_b0365","first-page":"6064","article-title":"A human prostatic epithelial model of hormonal carcinogenesis","volume":"61","author":"Wang","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2022.109036_b0370","doi-asserted-by":"crossref","first-page":"20090","DOI":"10.1073\/pnas.1117772108","article-title":"Estrogen receptor beta and 17beta-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer","volume":"108","author":"Muthusamy","year":"2011","journal-title":"PNAS"},{"key":"10.1016\/j.steroids.2022.109036_b0375","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/S0002-9440(10)63760-1","article-title":"Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis","volume":"164","author":"Zhu","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.steroids.2022.109036_b0380","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/me.2011-1101","article-title":"Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer","volume":"26","author":"Yang","year":"2012","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.steroids.2022.109036_b0385","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/pros.23017","article-title":"Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells","volume":"75","author":"Yang","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.steroids.2022.109036_b0390","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.mce.2016.11.016","article-title":"Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity","volume":"440","author":"Nelson","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.steroids.2022.109036_b0395","doi-asserted-by":"crossref","first-page":"15840","DOI":"10.1038\/ncomms15840","article-title":"Insufficient antibody validation challenges oestrogen receptor beta research","volume":"8","author":"Andersson","year":"2017","journal-title":"Nat. Commun."}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X22000745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X22000745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T10:08:30Z","timestamp":1758535710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X22000745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":79,"alternative-id":["S0039128X22000745"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2022.109036","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estrogen receptor expression is modulated in human and mouse prostate epithelial cells during cancer progression","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2022.109036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109036"}}